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I
Summary
Thermolability of 5,10-methylenetetrahydrofolate reduc­
tase (MTHFR) was examined as a possible cause of mild 
hyperhomocysteinemia in patients with premature vascu­
lar disease. Control subjects and vascular patients with 
mild hyperhomocysteinemia and with normohomocys- 
teinemia were studied. The mean (±SD) specific MTHFR 
activity in lymphocytes of 22 control subjects was 15.6 
(±4.7) nmol CH20 /m g  protein/h (range: 9.1-26,6), and 
the residual activity (±SD) after heat inactivation for 5 
min at 46°C was 55.3 (±12.0)% (range: 35.9-78.3). By 
measurement of MTHFR activity, two distinct subgroups 
of hyperhomocysteinemic patients became evident. One 
group (n -  11) had thermolabile MTHFR with a mean 
(±SD) specific activity of 8.7 (±2.1) nmol CH20/m g pro­
tein/h (range: 5.5 -12.7) and a residual activity, after heat 
inactivation, ranging from 0% to 33%. The other group 
(n = 28) had normal specific activity (±SD) of 21.5 (±7.2) 
nmol CH20 /m g  protein/h (range: 10.0-39.0) and a nor­
mal residual activity (±SD) of 53.8 (±9.2)% (range: 33.1- 
71.5) after heat inactivation, The mean (±SD) specific ac­
tivity of 29 normohomocysteinemic patients was 20.7 
(±6.5) nmol CH20/m g protein/h (range: 9.4-33.8), and 
the mean (±SD) residual activity after heat inactivation 
was 58.2 (±10.2)% (range: 43.0-82.0). Thus, in 28% of the 
hyperhomocysteinemic patients with premature vascular 
disease, abnormal homocysteine metabolism could be at­
tributed to thermolabile MTHFR.
introduction
Over the past decade, mild hyperhomocysteinemia has be­
come an established risk factor for premature vascular dis­
ease (Brattstrom and Lindgren 1992; Kang et al. 1992; Ue- 
land et al. 1992). Homocysteine is presumed to damage the
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endothelial cells, although the mechanism of its toxicity 
remains obscure (Blom and VandeMolen 1994).
Homocysteine accumulation may be caused by a meta­
bolic block in either the degradation of homocysteine to 
cystathionine or the remethylation of homocysteine to 
methionine (fig. 1). The classic form of severe hyperhomo­
cysteinemia is caused by cystathionine (3-synthase defi­
ciency. This enzyme catalyzes the formation of cystathio­
nine from homocysteine and serine. Another enzymatic 
cause of severe hyperhomocysteinemia is 5,10-methylene- 
tetrahydrofolate reductase (MTHFR) deficiency, which 
affects the remethylation of homocysteine to methionine. 
M THFR catalyzes the reduction of 5,10-methylenetet- 
rahydrofolate (methylene-THF) to 5-methyltetrahydrofo- 
late (Me-THF), in which flavin adenine dinucleotide (FAD) 
serves as cofactor (fig. 1).
Severe hyperhomocysteinemia due to M THFR defi­
ciency causes neurological abnormalities, mental retarda­
tion, arteriosclerosis, and thrombosis (Rosenblatt 1989). 
The biochemical characteristics are hyperhomocystinuria, 
reduced or low methionine concentrations in plasma, low 
plasma folate levels, and very low M THFR activity in both 
fibroblasts and lymphocytes (Wada et al. 1978; Harpey et 
al. 1981; Wendel et al. 1983). Low plasma-folate levels re­
sult from a lack of the M THFR product Me-THF, which 
is the main form of circulating folate, The clinical severity 
and the extent of biochemical derangement appear to be 
correlated with the degree of enzyme deficiency (Harpey 
et al. 1981; Rosenblatt 1989). In obligate heterozygotes for 
severe MTHFR deficiency the specific M TH FR  activity is 
~50%  of the normal mean, and it is unknown whether 
this condition is associated with an increased risk for vas­
cular disease (Kang et al. 1991 a).
Heterozygotes for cystathionine (3-synthase deficiency 
have reduced enzyme activity in cultured fibroblasts and 
also mild hyperhomocysteinemia, after methionine load­
ing (Boers et al. 1985a). Reduced cystathionine 0 -  
synthase activity in fibroblasts has also been found in the 
majority of vascular-disease patients with mild hyperho­
mocysteinemia, in two studies (Boers et al. 19856; Clarke 
et al. 1991). However, this finding could not be reconciled 
with the observations of M udd et al. (1981) that, in a large 
series of families with a homozygote cystathionine (3-syn­
thase deficient patient, the obligate carriers did not have
<(
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ciency, with one allele for the severe form and one allele 
for the thermolabile form, have also been described. These 
patients have a specific enzyme activity of ~ 25%  of the 
normal mean, and their MTHFR is probably thermolabile 
(Kang et al, 199'ltf).
The present study describes a modified method for mea­
surement of thermolabile MTHFR in isolated lympho­
cytes, Reference values were obtained from 23 healthy 
subject's. From our patient group with premature vascular 
disease (Franken et al. 1994) we selected 39 patients with 
and 29 without mild hyperhomocystcinemia, to study the 
relationship between mild hyperhomocystcinemia and 
thermolabile MTHFR.
homoserine
cysteine
SO i
Figure I Homocysteine metabolism. CS = cystathionine |J-syn 
thase; MS ~ methionine synthase; anti THF = tctraliydrofolatc.
an increased risk of vascular disease. While there is evi-
Subjects, Material, and Methods
Pot/ents and Controls
Patients with arteriosclerosis or venous thrombosis <55 
years of age were screened for mild hyperhomocys­
tcinemia by the methionine-loading test (0,1 g L-methio- 
nine/kg body weight) in University Hospital Nijmegen 
(Boers et al. 1985/?). Patients with hyperlipoproteinemia, 
hypertension, and diabetes mellitus were excluded. There 
were no other selection criteria.
Reference values for homocysteine concentrations, be-
dence of a h igh prevalence of mild hyperhomocystcinemia fore and after methionine loading, were obtained from 88 
in patients with vascular disease (Brattstrom and Lindgren 
‘1992; Kang et al. 1992; Ueland et al. 1992)—- even in pop­
ulations with the highest prevalence of homozygous cysta­
thionine (3-synthase deficiency, such as in Ireland-»the 
calculated number of heterozygotes is too low to account 
for the num ber of observed hypcrhomoeysteinemic vascu­
lar patients (Daly et al. 1993), In agreement with this ob- group. The mean ±  2 SD range of the reference group for 
servation, we (H. J. Blom, B. Fowler, G, H. J. Boers, and total homocysteine concentration was 4 -1 6  (.imol/litcr 
F. J. M. Trijbels, unpublished observations) and others (j, (skewness 0.9» kurtosisI .0) after fasting and 15-49 |im o l/ 
Kraus, personal communication) could not reproduce the liter after methionine loading (skewness 0.7, kurtosis
control subjects — 65 premenopausal women and 23 men, 
Reference values for folic acid and vitamin i\\2 levels were 
obtained from 68 control subjects— 45 premenopausal 
women and 23 men. Mild hyperhomocystcinemia was de­
fined as total homocysteine blood levels after methionine 
loading higher than the mean -h 2 SD of the reference
finding of lowered cystathionine ß-synthase activity in fi- ({fasln*0,3), Mean ±  2 SI) range for plasma folic acid was 5 .3-
broblasts of vascular patients with mild hyperhomocys- 22.5 nmol/liter (skewness 1,1, kurtosis 1.1) and for vita- 
teinemia. This suggests chat some aberration other than min Bu  84-487  pm ol/liter (skewness 0.9, kurtosis 1.0).
Four patients (8, 11, 16 and 23) were folate deficient (<5.3 
nmol/liter), and one patient (14) had reduced vitamin 
(79 pmol/liter). However, these patients showed no clas­
sical clinical symptoms of folate or vitamin Bi2 
As a reference, MTHFR activity was measured in a 
group of 23 healthy subjects, consisting of hospital per­
sonnel without any clinical evidence for vascular disease, 
Their mean (±SD) age was 32.7 (±7.4) years. One subject 
clearly showed thermolabile MTHFR and was excluded 
from the control group,
The presence of thermolabile MTHFR was studied in 
several groups of vascular patients, after their homocys­
teine status was established by methionine loading. One 
group with mild hyperhomocystcinemia consisted of 39 
mean but probably have thermostable M THFR (Kang et patients— 28 premenopausal women and 11 men— with 
al. 19916). Com pound heterozygotes for M THFR defi- proved vascular disease (17 patients with cerebral, 9 pa-
heterozygosity for cystathionine P-synthase deficiency is 
causing the hyperhomocysteinemia in vascular patients, 
Recently, a thermolabile variant of M THFR (Kang et al. 
1988tf, 19886 ,1991a, 1991 6) was shown to be caused by a 
mutation different from that causing the severe form of 
MTHFR deficiency, Homozygotes for thermolabile 
MTHFR deficiency have a specific activity of ~-50% of 
normal, and a residual activity after heat inactivation of 
<30%, compared with 50% residual activity in control 
subjects. Kang et al. (19916) reported an incidence of ho­
mozygote thermolabile M TH FR  deficiency of 17% in a 
group of 212 patients with coronary artery disease. Obli­
gate hcterozygotcs for thermolabile M THFR deficiency 
have a specific enzyme activity of ~ 7 5 %  of the normal
144 A m .]. H um. Genet. 56:142-150, 1995
tients with peripheral, and 5 patients with coronary arterial 
occlusive disease and 8 patients with venous thrombosis). 
The mean (±SD) age of these patients at the time of study 
was 40.3 (±8.9) years. The mean (±SD) age at clinical onset 
of the vascular abnormalities in this group was 35.6 
(±10.1) years.
Another group consisted of 29 normohomocysteinemic 
patients — 14 female and 15 male— with premature vas­
cular disease (21 patients with cerebral, 6 patients with pe­
ripheral, and 1 patient with coronary arterial occlusive dis­
ease and 1 patient with venous thrombosis). Their mean 
(±SD) age at the time of study was 43.8 (±12.5) years. The 
mean (±SD) age of clinical onset of vascular disease in this 
group was 40.3 (±11.4) years.
Potassium phosphate, L-(+)-ascorbic acid, 35% formal­
dehyde, toluene, and acetic acid were obtained from 
Merck. FAD (disodium salt), menadione sodium bisulfite, 
dimedone, and Me-THF (barium salt) were obtained from 
Sigma Chemical. EDTA was obtained from Fluka Bio» 
Chemika, and [Me-HC] Me-THF (50 mCi/mmol, barium 
salt) was obtained from Amersham International. An Ep- 
pendorf 5436 thermomixer was used for preincubating the 
enzyme extract and for incubating the incubation mixture.
Lymphocytes were isolated from 20 ml heparinized 
blood by using Lymphoprep (Nycomed Pharma AS) (Jon- 
dal et al. 1972) and were washed twice with Hank’s buffer 
(ICN Biomedicals). The cell pellet was stored at — 80°C 
until enzyme assay.
The MTHFR activity was determined radiochemically 
in lymphocytes, in its physiological reverse direction (fig. 
1). [Me-14C] Me-THF served as the substrate in the pres­
ence of menadione as electron acceptor. Activities were 
measured using a modified method of Kang et al. (1991fc). 
The cells were resuspended in 50 mM potassium phos­
phate buffer pH 7.2, were frozen and thawed three times, 
and were centrifuged 40 min at 15.8 X 103 g. A part of 
the supernatant was preincubated for 5 min at 46°C, to 
determine the heat stability. FAD was omitted during this 
heat inactivation (Rosenblatt and Erbe 1977). The incuba­
tion mixture, with a final volume of 600 pi, consisted of 
0.18 M potassium phosphate buffer pH 6.8, 1.15 mM 
EDTA pH 7.0, '11.5 mM ascorbic acid, 54 pM FAD, 20 
pM  [Me-HC] Me-THF (5.0 X 10s dpm), 3.5 mM menadi­
one, and a maximum of 250 pi enzyme extract (preincu­
bated supernatant or normal supernatant), The incubation 
was started by addition of menadione and lasted for 20 
min in the dark at 37°C. The blank contained all the com­
ponents of the incubation mixture except enzyme extract. 
The incubation was terminated by the addition of 10 pi of
1.0 M carrier formaldehyde, 50 pmol dimedone in 200 jLtl 
ethanohwater (1:1), and 100 jixl 3.0 M potassium acetate, 
pH 4.5. The reaction mixture was heated at 95°C for 15 
min, after which it was cooled on ice for ~ 1 0  min. The 
reaction mixture-was added to 3.0 ml toluene and was 
stirred vigorously for 15 s. After low-speed centrifugation,
2.0 ml of the toluene phase was taken for measurement of 
radioactivity. Protein was determined by the method of 
Lowry et al. (1951). Enzyme activity is expressed as nmol 
of formaldehyde form ed/m g pro te in /h .
Cystathionine ß-synthase activity was measured as de­
scribed elsewhere (Fowler et al. 1978; Boers et al. 1985#), 
without addition of pyridoxal phosphate to the assay mix­
ture in cultured fibroblasts of 10 vascular hyperhomocys- 
teinemic patients. For comparison, cystathionine ß-syn­
thase activities were also measured in fibroblasts of 13 ob­
ligate heterozygotes for cystathionine ß-synthase and in 12 
control subjects.
Total (free plus protein-bound) homocysteine concen­
trations, fasting and after methionine loading, were mea­
sured in EDTA plasma, by means of high-performance liq­
uid chromatography by using fluorescence detection (Te 
Poele-Pothoff et aL, in press). Folic acid and vitamin B12 
levels were determined in heparinized plasma, and vitamin 
B6 levels were determined in whole blood, by routine hos­
pital assays.
I
Statistics
Rank-sum two-sample test and the Fisher’s exact test 
(two-tail) were applied. Normal distribution was supposed 
to be present in case the skewness and kurtosis tests 
ranged from —1 to +1. Spearman rank correlation was 
used for determining correlations.
Results
Pat/ents and Controls
Twenty-three healthy subjects were studied to obtain 
reference values. One subject was excluded from the con­
trol group because of thermolabile M THFR deficiency, 
with a specific activity of 7.7 nmol CH 20 /m g  p ro te in /h  
and a residual activity after heat inactivation of 15.6%. In 
the other 22 control subjects a mean (±SD) specific 
M THFR activity of 15.6 (±4.7) nmol CH 20 /m g  p ro te in / 
h (range: 9.1 -26.6) and a mean (±SD) residual activity after 
heat inactivation of 55.3 (±12.0)% (range: 35.9-78,3) was 
observed. In concordance with Kang et al, (1988a, 1988b, 
1991b), thermolabile M THFR was defined as a specific ac­
tivity of 50% of the normal mean and a residual activity 
after heat inactivation of <36.0% of the initial activity, 
The hyperhomocysteinemic vascular patients («=39) 
could be divided into two distinct subgroups (table 1). One 
group (n= 11) with thermolabile M THFR, showed a mean 
(±SD) specific activity of ~ 5 0 %  of the normal mean, 8.7 
(±2.1) nmol CH20 /m g  p ro te in /h  (range: 5,5 -12,7), and a 
residual activity after heat inactivation ranging from 0% to 
33.0%, The specific M THFR activity of the thermolabile 
group showed a small overlap with the control group, so 
heat inactivation was employed to discriminate between 
control subjects and patients with thermolabile M THFR
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residual MTHFR activity
specific MTHFR activity (nmol CH20/mg protein.h)
Figure 2 Residual M THFR activity after heat inactivation, versus 
the specific activity in lymphocytes of hyperhomocysteinemic patients 
and control subjects. The dashed square contains the patients with ther­
molabile MTHFR. = Control subjects; and ♦  =  hyperhomocys­
teinemic vascular patients.
(fig. 2). The other group of hyperhomocysteinemic vascu­
lar patients («=28) had a normal specific activity (±SD) of 
21.5 (±7.2) nmol CH 20 /m g p ro te in /h  (range: 10.0-39.0) 
and a residual activity after heat inactivation of 53.8 
(±9.2)% (range: 33.1-71.5). The mean (±SD) specific ac­
tivity of the 29 normohomocysteinemic vascular patients 
was 20.7 (±6.5) nmol CH 20 /m g  p ro te in /h  (range: 9 .4 - 
33.8), and their mean (±SD) residual activity after heat in­
activation was 58.2 (±10.2)% (range: 43.0-82,0). Among 
the 29 normohomocysteinemic patients, no thermolabile 
M THFR activity was observed (table 1), which was sig­
nificantly different (P <  .002) from the incidence of 11 
cases of thermolabile M THFR among the 39 hyperhomo­
cysteinemic patients.
Cystathionine ß-synthase activity was measured in avail­
able fibroblasts of 10 patients with mild hyperhomocys- 
teinemia (patients 3 ,1 0 ,1 3 ,1 6 ,1 8 ,2 0 ,2 3 ,2 5 ,2 7 , and 33). 
Their enzyme activities were, respectively, 5.0, 6.5, 9.5, 
7.9,1.6, 5.8, 3.3, 8.0, 6.4, and 6.0 nmol cystathionine/mg
protein /h . (normal range 2 .3 -18 .2  nmol cystathionine/ 
mg protein/h; n “  1.2). So, only patient number 18 had 
activity within the range of obligate heterozygotes for cys­
tathionine ß-synthase deficiency (0.25-2.4 nmol cystathi­
onine/m g pro tein /h ; n = 13). Only two studied patients 
(3 and 10) had thermolabile M THFR, and their cystathio­
nine ß-synthase activities were normal.
The 11 patients with thermolabile M THFR had diverse 
clinical abnormalities: 4 patients suffered from cerebral ar­
tery disease; 2 suffered from peripheral artery disease; 1 
suffered from coronary artery disease; and 4 patients had 
venous thrombosis. Among the patients with thermolabile 
M THFR, np correlation was observed between specific
MTHFR activity and either fasting total homocysteine or 
total homocysteine after methionine loading. Among all 
patients with normal MTHFR activity, age did not corre­
late with either specific MTHFR activity or residual 
M THFR activity after heat inactivation. The mean (±SD) 
plasma folic acid level of the patients with thermolabile 
M THFR (7.9 ±  2.9 nmol/liter) was significantly lower (P 
<  .0002) than that of the reference group (13.6 ±  3.8 
nmol/liter). However, the plasma folic acid levels of the 
total group of hyperhomocysteinemic patients (9.2 ±  3.4) 
were also significantly lower (P <  0,0001) than those of the 
reference group. The mean (±SD) vitamin B12 concentra­
tion of the thermolabile MTHFR-deficient patients (222 
±  75 pmol/liter) was significantly different (P = .052) from 
that of the reference group (290 ± 115  pmol/liter), but the 
vitamin B12 levels of the total group of hyperhomocys­
teinemic patients (227 ±  84) were also significantly lower 
(P <  .02) than those of the reference group.
Assay
After incubation at 37°C, the formaldehyde produced 
was derivatized by dimedone and the resulting product, 
formaldemethone, was extracted with toluene. Addition 
of carrier formaldehyde increased the amount of labeled 
formaldemethone and therefore the specific M THFR ac­
tivity (fig, 3). Dimedone and formaldehyde react at a ratio 
of 2:1 (Ruyter 1980). This means that the amount of 
dimedone must always exceed twice the amount of form­
aldehyde present. We investigated the derivatization 
method by optimizing the carrier formaldehyde concen­
tration at a constant dimedone concentration and by opti­
mizing the dimedone concentration at a constant carrier 
formaldehyde concentration. Optimal derivatization and 
extraction was achieved by addition of 10 jimol carrier 
formaldehyde and 50 jimol dimedone.
Three different blanks were tested: (1) the reaction mix­
ture including the enzyme extract and no incubation at 
37°C; (2) the reaction mixture incubated at 37°C without 
the enzyme extract; and (3) the reaction mixture and addi­
tion of the enzyme extract after the incubation at 37°C. 
I»lank 1 was inadequate because it resulted in recovery of 
much less radioactivity than either blank 2 or 3. N o 
difference between blank 2 and 3 was observed (data not 
shown). Blank 2 was used in this study, because it required 
no enzyme extract.
MTHFR activity depends on the concentration of the 
cofactor FAD. A maximum activity was observed at 50 
jliM  FAD. In all assays, 54 (iM FAD were used. Formalde­
hyde production was linear, with incubation time up to 40 
min and with amount of enzyme between 10 and 250 \ig 
protein. The incubation time used was 20 min, and the 
amount of enzyme extract added varied from 22 to 150 |ig 
protein. A (Michaelis constant (Km) for Me-THF of 19 (J.M
was observed. Overall, the modifications resulted in higher 
specific MTHFR activities in lymphocytes than were re-
t
Table I
Sex, Age, Homocysteine Concentrations Fasting and after Loading, and Specific and Residual M TH FR  Activity after Heat 
inactivation in Patients with Premature Vascular Disease
Patient
Hyperhomocysteinemic 
patients with 
normal MTHFR 
activity:
12 ................................
13  
14  
15  
16  
17  
18  
19  
20  
21 .................................
22 .................................
23  
24  
25  
26  
27  
28  
29  
30  
31  .......................
32  
33  
34  
35  
36  
3 7  
38  
39  
Mean ..........«...........
S D .............................
Normohomocysteinemic
patients:
40  
41  
42  
43  
Sex
Hyperhomocysteinemic 
patients with 
therm olabiJe
MTHFR:
F
F
F
M
M
F
F
M
F
F
F
F
M
M
F
M
F
F
M
F
F
F
M
M
F
F
F
F
Age"
Hcysb 
at 0 h
Hcysc 
at 6 h
F
M
M
M
46
51
31
50
50
51 
S3 
43
39 
46 
28
43 
29
40 
33 
42 
20 
19 
35
44
41 
40 
63 
48 
46 
48
42 
46 
41.7
9.9
10
11
27
20
21
14
nd
34
19
14 
10 
nd
144
13
12
nd
30
16
26
15 
13
nd
12
23
7
22
61
11
24.4
27.9
77
75
116
54
68
56 
75 
71 
50
63
54
115
148
60
75
69
57 
52 
50 
61 
62 
84 
61 
52 
59 
74
145
67
73.2
26.3
47
48 
25 
41
13 
15
14 
11
40
44
31
31
Specific M THFR Activity 
(nmol CH20 /m g  
protein/h)
23.1 
22,6 
11.6
12.5 
25.9
14.7
23.2
13.5
17.8
30.4
22.2
18.7 
10.0
26.8
30.1
28.1
10.3
18.6 
21.7
39.0 
19.6 
23.2
16.5
18.4
16.5 
28.9
25.6
33.1 
21.5
7.2
23.7
31.3
22.1
24.6
Residual M THFR 
Activity
(%)
1 ............... F 28 20 57 9.5 19.4
2 ............... F 52 13 94 5.5 0
3 ............... F 26 19 51 ■ 8.4 5.4
4 ............... F 46 13 54 9.0 5.5
5 ............... F 49 17 57 6.5 29.8
M 21 31 16 12.7 26.5
7 ............... F 35 18 67 7.3 19.5
8 ................ M 49 32 68 8.2 31.5
9 ................ F 37 27 52 11.9 33.0
10 ............. F 40 17 88 8.6 11.1
11 ............. F 29 38 92 8.2 29.2
Mean .... 37.5 22.3 68.7 8.7 19.2
S D ......... 10.6 8.4 16.4 2.1 11.9
52.7
35.5
49.7
52.0
71.5
54.1
67.7
47.7
48.3
55.1
59.3
52.2 
62.0
63.4
54.6 
61.1
43.0
56.8
46.4
67.7
59.8
47.4
49.5
63.1
57.5 
42.4
52.9
33.1 
53.8
9.2
52.7 
71.6
58.8
50.8
(icontinued)
Table I (continued)
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Patient Sex Agen
Hcysb 
at 0 h
Hcysc 
at 6 h
Specific MTHFR Activity 
(nmol CH20 /m g  
protein/h)
Residual MTHFR 
Activity
(%)
Normohomocysteinemic
patients:
(continued)
44 F 47 13 49 30.5 82.0
45 .................................. F 27 11 28 14.8 64.9
46 .................................. M 55 12 43 19.6 61.2
47 ..................... ............ M 56 14 34 14.0 47.1
48 .................................. F 37 10 32 11.4 43.0
49 .................................. M 53 8.7 25 33.8 76.2
50 .................................. M 41 7.5 22 18,1 49.7
51 .................................. M 40 13 37 16.0 61*9
52 .................................. F 22 10 27 25.8 60.9
53 .................................. M 55 13 38 18.9 64.0
54 .................................. F 22 11 28 14.8 65.0
55 .................................. F 35 7.8 27 20.5 55.0
56 .................................. F 52 17 42 13.0 50.0
57 .................................. M 46 15 46 20.0 68.7
58 .................................. F 48 13 40 23,7 52.7
59 .................................. M 39 13 39 9.4 49.2
60 .................................. F 46 8.7 21 29,4 67.7
61 .................................. F 39 13 33 17.0 43.2
62 .................................. F 31 11 32 21.3 69.2
63 ........................*......... M 42 11 31 24.6 50.8
64 .................................. M 47 10 32 28.6 46.3
65 .................................. F 51 17 42 13.0 50.0
66 .................................. F 34 15 41 26.9 66.2
67 .................................. M 56 12 43 19.6 61.2
68 .................................. M 57 14 34 14.0 47.1
Mean ........................ 43.8 12.2 34,9 20.7 58.2
S D ............................. 12.5 2.5 7.3 6.5 10.2
0 Age at the time of this study, 
b Total homocysteine, fasting, nd -  not determined. 
c Total homocysteine, after methionine loading.
ported elsewhere (Kang et al. 1988^ 1988b, 1991#,
1991 b).
The thermolability of M THFR in the enzyme extract of 
pooled lymphocytes of controls was examined by preincu­
bating for 5 min at 37° C, 40°C, 46°C, and 49°C. Incubation 
at 49°C resulted in a 70% loss, at 46°C in a 53% loss, and 
at 40°C in a 17% loss of activity. Preincubation at 46°C 
resulted in a 77% loss of enzyme activity at 20 min, 53% 
loss at 10 min, 43% loss at 5 min, and 18% loss of enzyme 
activity at 2 min (fig. 4). H eat inactivation was performed 
by incubating the enzyme extract for 5 min at 46°C, thus 
allowing a reliable distinction between thermolabile and 
thermostable MTHFR, in patients and control subjects.
Discussion
In this study, the thermolabile form of M THFR was ob­
served in 11 of 39 premature-vascular-disease patients
with mild hyperhomocysteinemia after methionine load­
ing. Nine of these 11 patients were hyperhomocysteinemic 
in the fasting state. No thermolabile M THFR was ob­
served among 29 normohomocysteinemic patients with 
premature vascular disease, and of 23 healthy subjects 1 
case had thermolabile MTHFR. These findings indicate 
that thermolabile MTHFR is one of the causes leading to 
mild hyperhomocysteinemia, established by methionine 
loading, in patients with vascular disease.
S-adenosylmethionine is a major regulating compound 
in homocysteine metabolism because it activates cystathi­
onine p-synthase and inhibits MTHFR (Finkelstein 1990). 
Plasma homocysteine concentration is supposed to reflect 
the capacity of homocysteine remethylation in the fasting 
state because of the low S-adenosylmethionine levels, 
whereas the homocysteine concentration after oral load­
ing with unphysiologic, high amounts of methionine is be­
148 A m ,] . H um . Genet. 56:142- ISO, I WS
sp ec ific  MTHFR activity (nmol CH20/mg protein.h)
carrier form aldehyde (jjmol)
Figure 3 Effect of variation of the amount of carrier formalde­
hyde on the derivatization of labeled formaldehyde with dimedone at 
two different concentrations. Q =  6 jumol dimedone; and □  = 50 jamol 
dimedone.
lieved to evaluate the cystathionine p-synthase status 
(Kang et al. 1992; Ueland et al. 1992). However, in the 
present study, all vascular patients with the thermolabile 
form of M T H F R  had elevated homocysteine levels after 
loading and not always in the fasting state. Probably, the 
folate-dependent homocysteine remethylation contri­
butes to homocysteine conversion not only in the fasting 
state but also after methionine loading.
Cystathionine j3-synthase activity was assayed in 10 of 
the 39 vascular patients with mild hyperhomocysteinemia, 
including two patients (3 and 10) with thermolabile 
M THFR. All except one (patient 18) had normal cystathi­
onine (3-syntbase activity. This indicates that decreased
cystathionine (3-synthase activity is not the major cause oi 
hyperhomocysteinemia in patients with premature vascu­
lar disease,
Kang et al. (19916) observed an incidence of 17% of 
thermolabile M THFR in a group of 212 patients with cor­
onary arterial disease. Their homocysteine metabolism 
was not examined by means of a methionine-loading test. 
In a previous study (Franken et al. 1994) we observed, in a 
large group of patients with diverse forms of vascular dis­
ease, a prevalence of hyperhomocysteinemia of 24% by us­
ing methionine-loading tests. The present paper shows 
that ~ 2 8 %  of such hyperhomocysteinemic patients have 
the thermolabile form of M THFR. Thus, an incidence of 
thermolabile M THFR of 7% among our total group of 
vascular patients can be calculated, which is lower than 
what Kang et al. (19916) observed among coronary pa­
tients.
The hyperhomocysteinemic patient group consisted of 
more female patients than male, compared with the nor- 
mohomocysteinemic patient group. Hyperhomocys­
teinemic women may be more susceptible to developing 
vascular disease than are hyperhomocysteinemic men 
(Franken et al. 1994). The age at onset of vascular disease 
among the thermolabile M T H FR -defic ien t patients var­
ied from 18 to 50 years. The clinical expression of vascular 
disease among the 11 patients with thermolabile M TH FR  
was very diverse, including cerebral, peripheral, and coro­
nary arterial disease and venous thrombosis. Therefore, 
thermolabile M THFR is a risk factor no t only for coro­
nary arterial disease, as reported by Kang et al. (1988#; 
19916), but probably for vascular disease in general.
An incidence of the homozygous form of thermolabile 
M THFR of 5% in the normal population is reported (Kang 
et al. 1988#j 19916). This is consistent with our finding of 
1 thermolabile M TH FR -deficient subject among 23 
healthy subjects. Thus, the heterozygous form must have
pre lncubatlon  tem p era tu re  ( C) preincubation  time (min)
residual MTHFR activity residual MTHFR activ ity
4
F i g u  r e  4  Left panel, Effect of preincubation for 5 min at different temperatures on the residual M TH FR activity (<$), Right panel, Effect of 
variation of preincubation time at' 46°C on the residual MTHFR activity (□).
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an incidence of ~ 2 2 %  in the normal population. Such a 
high frequency of this thermolabile M THFR mutation 
might be explained by a concomitant beneficial effect of 
the mutation. Perhaps, in times of starvation, a reduced 
M THFR activity decreases homocysteine remethylation 
and preserves the available one-carbon moieties of the 
THF derivatives for the vital synthesis of purines and thy­
midine.
Severe M THFR deficiency is very resistant to many ho- 
mocysteine-lowering and methionine-elevating forms of 
therapy, including folates, methionine, pyridoxine, vita­
min B12, and carnitine (Wada et al 1978; Harpey et al. 
1981; Rosenblatt 1989). Betaine appears the best choice 
of therapy (Benevenga '1984; Wendel and Bremer 1984; 
Hyland et al 1988; Rosenblatt 1989). It enhances the re­
methylation of homocysteine to methionine via an alterna­
tive pathway (fig. 1), and methionine levels increase at the 
expense of homocysteine. Logical choices of therapy for 
thermolabile M TH FR-deficient patients seem to be folic 
acid and betaine. Riboflavin could also be an appropriate 
option, since FAD is the cofactor of M THFR and may 
stabilize the mutant M THFR. Two patients with thermo­
labile M THFR and mild hyperhomocysteinemia showed 
a dramatic decrease of total homocysteine concentration 
after folic acid therapy (Kang et al. 19886). Folic acid ad­
ministration may increase the concentrations of methyl- 
ene-THF which is the substrate of MTHFR.
On the relationship between vascular disease and mild 
hyperhomocysteinemia due to a 50% reduction in 
M THFR activity the following considerations can be 
made: (i) In the vascular wall THF-dependent remethyla­
tion constitutes the primary mechanism for homocysteine 
conversion. The betaine-homocysteine methyl transferase 
is present only in the liver and maybe in the kidney, and 
the K m of cystathionine (3-synthase is >10 times higher 
than that of the enzymes involved in THF-dependent ho­
mocysteine remethylation (Finkelstein 1990). (ii) Mild hy­
perhomocysteinemia is likely caused by a combination of 
genetic and environmental factors, including methionine, 
betaine, choline, folate, vitamin B6, and B12. (iii) In addi­
tion, although thermolabile M THFR and hyperhomocys­
teinemia are correlated, and hyperhomocysteinemia is a 
risk factor for vascular disease, some other effect of ther­
molabile MTHFR, besides its resultant hyperhomocys­
teinemia, may put patients at risk for vascular disease. In 
conclusion, thermolabile M THFR is the most likely cause 
of abnormal homocysteine metabolism in ~ 2 8 %  of the 
vascular patients with mild hyperhomocysteinemia.
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